CRISPR Therapeutics' stock faces challenges with slow Casgevy adoption and competition. See how CRSP stock remains a cautious ...

CRISPR Therapeutics (CRSP) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) have been assigned a consensus recommendation of “Hold” from ...

After hours: March 12 at 7:59:48 PM EDT Loading Chart for CRSP ...

Equities researchers at Zacks Research upped their Q2 2025 earnings estimates for CRISPR Therapeutics in a report issued on ...

A new review in Engineering reveals that CRISPR technologies are revolutionizing regenerative medicine. Scientists from ...

Spread the love In an era of rapid technological advancement, social upheaval, and environmental challenges, certain ...

In an unprecedented procedure, CRISPR gene editing has been used to treat cancer. A research team from Tel Aviv University, led by Razan Masarwy, successfully used CRISPR to cut a gene from head and ...

As of 10:03:11 am GMT-4. Market open. Loading Chart for CRSP ...